Acquisitions: CIGEN, Nurtec, and Growth Expectations

Borla defends Pfizer's M&A spending, discusses CIGEN expectations, and outlines potential oncology upside.

Play episode from 33:13

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!